Agendapunt opsteller R.M.A. Spriensma doorkiesnummer e-mail firstname.lastname@example.org Vergadernotitie voor de Bestuurscommissie en het Dagelijks Bestuur d.d. 29 november 2013 Onderwerp: wijziging vervanging fluistervloot Aanleiding In de afgelopen begrotingen (2013 en 2014) heeft het Parkschap een wijziging van de fluistervloot doorgevoerd (meerjarenbegroting)
Microsoft word - wada updatesThe World Anti-Doping Agency (WADA) has published the 2010 Prohibited List which will come into effect on 1 January 2010. The Prohibited List is an international standard that outlines the substances and methods that are prohibited in sport. I encourage you and your relevant team members to familiarise yourself with the new Prohibited List to ensure your athletes are ready for the change on 1 January 2010. Please find attached a summary of significant changes for your convenience. Please pay particular attention to the following key changes. The status of salbutamol and salmeterol (used for the treatment of asthma). Therapeutic use of inhaled salbutamol (maximum 1600 micrograms per day) and salmeterol will not be prohibited as of 1 January Supplemental oxygen (hyperoxia) will no longer be prohibited. The status of platelet-derived preparations (such as Platelet Rich Plasma (PRP), ‘blood spinning’) has been clarified by WADA. It will be prohibited when administered by intramuscular route, but other routes of administration will require a declaration of use. Pseudoephedrine will be reintroduced to the Prohibited List and will be prohibited above 150 micrograms These changes are effective from 1 January 2010. If you have any questions regarding the new Prohibited List, please contact ASADA As you may already be aware, Abbreviated Therapeutic Use Exemptions (ATUEs) for beta-2 agonists have been Please note that all ATUEs will expire on 31 December 2009. Any athlete with an existing ATUE will need to apply for a Therapeutic Use Exemption (TUE) before this time. Please see attached table which outlines which body (either their International Federation or ASDMAC) athletes should be applying to for their TUEs. We are expecting that ASDMAC will be quite busy processing TUE applications in the lead up to 31 December 2009, so it is strongly recommended that athletes undertake the appropriate medical tests and apply for their TUE ASAP to allow time for the TUE to be processed. Athletes who do not have a TUE approved by 1 January 2010 will not be covered by their previous ATUE. For more information about TUE applications, please visit the ASDMAC website at www.asdmac.gov.au or call 13 000 ASADA and press ‘4’ for ‘TUEs’. ASADA will be conducting a comprehensive testing program in the lead up to the 2010 New Delhi Commonwealth Games. As a part of this program, ASADA will be testing every athlete in the 2010 Australian Commonwealth Games Team (this testing may also include shadow squad members who do not make the final This testing program began on 3 October 2009 (one year out from the Games) and will continue until the Advice from the World Anti-Doping Agency (WADA) The status of inhaled salbutamol and salmeterol, beta-2 agonists, will change. Therapeutic use of inhaled salbutamol (maximum 1600 micrograms per day) and need a TUE, just a declaration of use at salmeterol will not be prohibited as of 1 January 2010 with If the urinary concentration is above 1,000 nanograms per millilitre, there will be a presumption that the substance was not taken by inhalation and the athlete will have to demonstrate through a controlled pharmacokinetic study that the level found in his urine was the result of Pseudoephedrine will be reintroduced to the List and will be prohibited above 150 micrograms per millilitre. Athletes are to stop taking pseudoephedrine at least 24 For therapeutic applications in-competition, consider the use of alternative permitted medications upon previous prior to or during competition. There are consultation with a physician, or apply for a Therapeutic The threshold level has been established based on the intake of therapeutic doses, defined as a maximum daily four (4) daily administrations (one every 4-6 hours) of a 60mg pill (or 2 x 30mg pills), (8 Codral original cold and pseudoephedrine as directed. Taking two (2) daily administrations (one every 12 hours) of a in-competition and therefore a sanction. one (1) daily administration of a 240mg pill. In line with this dosing regimen, the intake, for example, of a single daily dose of 3 x 60mg pills constitutes a supratherapeutic administration that may lead to an The status of platelet-derived preparations (e.g. Platelet- Rich Plasma (PRP), ‘blood spinning’) has been clarified and is prohibited when administered by intramuscular route. Other routes of administration will require declaration of use in compliance with the International Standard for TUEs. Injections of platelet-derived preparations into joints will not require Prohibited under S5 as a plasma expander. Supplemental oxygen is no longer prohibited. If an athlete has an IV prior to transport to hospital and is hospitalised, no TUE is Intravenous infusion Intravenous infusions are prohibited except for those legitimately received in the course of hospital admissions or To manage severe dehydration out of Using a drip to re-hydrate is prohibited No further collections or analyses will be required in cases where the testosterone to epitestosterone (T/E) ratio is greater than 4 and an isotope ratio mass spectrometry (IRMS) test or any other reliable analytical method has not revealed evidence of exogenous administration of a Glossary of terms TUE: athletes may at times require the use of a prohibited medication to treat a legitimate medical condition. A TUE allows athletes to use, for therapeutic purposes only, a medication that would be otherwise prohibited. Athletes apply to the Therapeutic Use Exemption Committee, which in Australia is the Australian Sports Drug Medical Advisory Committee. Declaration of use: some substances on the Prohibited List are frequently used to treat athletes’ medical conditions. Where the route of administration is not prohibited, the athlete is required to note the use of the prohibited substance. This can be done during a testing session by noting the use on the Doping Control Form, or it can be done by emailing email@example.com with the sport copied in, detailing the athlete’s: name date of birth sport address substance name of treating doctor and circumstances of use. Route of administration: the method of using a substance. For example: nasal, oral, or local Isotope ratio mass spectrometry (IRMS): an analytical technique which accurately determines the abundance of naturally occurring isotopes for a given compound. Platelet-Rich Plasma (PRP) therapy: removing blood from an individual’s body, spinning the blood to make serum or plasma enriched with platelets, and injecting the platelet-enriched fluid at an injured site to improve the body’s ability to heal and speed recovery.
TUEs for athlete types
THERAPEUTIC USE EXEMPTIONS FOR ATHLETE TYPES * if competing internationally, check TUE requirements with the relevant International Federation ^ in-advance TUE can be applied for (if athlete wishes) # declare on ADAMS where possible (some International Federations require a declaration form) www.asdmac.gov.au | +61 (0)2 6222 4232 | p1 of 1 | Updated May 2009 | Fact Sheet 02
Monday, PM, Arkansas Ballroom D, PHYSIOLOGY Plasma Amino Acid Levels and Growth Per- Susceptibility to heat stress in fast and slow formance of Broilers Fed Supplemental L-Arginine During growing turkey lines. L. J. Mills*1 , 2, M. A. Mitchell1, and M. Cool Temperature Exposure. C. A. Ruiz-Feria*1, M. T. Kidd2, Mahon2, 1 Roslin Institute (Edinburgh), Midlothian, UK, 2 Universit